Review: Glycation of human serum albumin

Jeanethe Anguizola, Ryan Matsuda, Omar S. Barnaby, K. S. Hoy, Chunling Wa, Erin DeBolt, Michelle Koke, David S. Hage

Research output: Contribution to journalReview article

160 Citations (Scopus)

Abstract

Glycation involves the non-enzymatic addition of reducing sugars and/or their reactive degradation products to amine groups on proteins. This process is promoted by the presence of elevated blood glucose concentrations in diabetes and occurs with various proteins that include human serum albumin (HSA). This review examines work that has been conducted in the study and analysis of glycated HSA. The general structure and properties of HSA are discussed, along with the reactions that can lead to modification of this protein during glycation. The use of glycated HSA as a short-to-intermediate term marker for glycemic control in diabetes is examined, and approaches that have been utilized for measuring glycated HSA are summarized. Structural studies of glycated HSA are reviewed, as acquired for both in vivo and in vitro glycated HSA, along with data that have been obtained on the rate and thermodynamics of HSA glycation. In addition, this review considers various studies that have investigated the effects of glycation on the binding of HSA with drugs, fatty acids and other solutes and the potential clinical significance of these effects.

Original languageEnglish (US)
Pages (from-to)64-76
Number of pages13
JournalClinica Chimica Acta
Volume425
DOIs
StatePublished - Oct 1 2013

Fingerprint

Serum Albumin
Medical problems
Proteins
Thermodynamics
Sugars
Amines
Blood Glucose
Fatty Acids
Degradation
Pharmaceutical Preparations

Keywords

  • Diabetes
  • Drug-protein binding
  • Glycated albumin
  • Glycation
  • Human serum albumin
  • Protein modification

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Anguizola, J., Matsuda, R., Barnaby, O. S., Hoy, K. S., Wa, C., DeBolt, E., ... Hage, D. S. (2013). Review: Glycation of human serum albumin. Clinica Chimica Acta, 425, 64-76. https://doi.org/10.1016/j.cca.2013.07.013

Review : Glycation of human serum albumin. / Anguizola, Jeanethe; Matsuda, Ryan; Barnaby, Omar S.; Hoy, K. S.; Wa, Chunling; DeBolt, Erin; Koke, Michelle; Hage, David S.

In: Clinica Chimica Acta, Vol. 425, 01.10.2013, p. 64-76.

Research output: Contribution to journalReview article

Anguizola, J, Matsuda, R, Barnaby, OS, Hoy, KS, Wa, C, DeBolt, E, Koke, M & Hage, DS 2013, 'Review: Glycation of human serum albumin', Clinica Chimica Acta, vol. 425, pp. 64-76. https://doi.org/10.1016/j.cca.2013.07.013
Anguizola J, Matsuda R, Barnaby OS, Hoy KS, Wa C, DeBolt E et al. Review: Glycation of human serum albumin. Clinica Chimica Acta. 2013 Oct 1;425:64-76. https://doi.org/10.1016/j.cca.2013.07.013
Anguizola, Jeanethe ; Matsuda, Ryan ; Barnaby, Omar S. ; Hoy, K. S. ; Wa, Chunling ; DeBolt, Erin ; Koke, Michelle ; Hage, David S. / Review : Glycation of human serum albumin. In: Clinica Chimica Acta. 2013 ; Vol. 425. pp. 64-76.
@article{f3ae4c89f9564ce9aa98800f68db6396,
title = "Review: Glycation of human serum albumin",
abstract = "Glycation involves the non-enzymatic addition of reducing sugars and/or their reactive degradation products to amine groups on proteins. This process is promoted by the presence of elevated blood glucose concentrations in diabetes and occurs with various proteins that include human serum albumin (HSA). This review examines work that has been conducted in the study and analysis of glycated HSA. The general structure and properties of HSA are discussed, along with the reactions that can lead to modification of this protein during glycation. The use of glycated HSA as a short-to-intermediate term marker for glycemic control in diabetes is examined, and approaches that have been utilized for measuring glycated HSA are summarized. Structural studies of glycated HSA are reviewed, as acquired for both in vivo and in vitro glycated HSA, along with data that have been obtained on the rate and thermodynamics of HSA glycation. In addition, this review considers various studies that have investigated the effects of glycation on the binding of HSA with drugs, fatty acids and other solutes and the potential clinical significance of these effects.",
keywords = "Diabetes, Drug-protein binding, Glycated albumin, Glycation, Human serum albumin, Protein modification",
author = "Jeanethe Anguizola and Ryan Matsuda and Barnaby, {Omar S.} and Hoy, {K. S.} and Chunling Wa and Erin DeBolt and Michelle Koke and Hage, {David S.}",
year = "2013",
month = "10",
day = "1",
doi = "10.1016/j.cca.2013.07.013",
language = "English (US)",
volume = "425",
pages = "64--76",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - Review

T2 - Glycation of human serum albumin

AU - Anguizola, Jeanethe

AU - Matsuda, Ryan

AU - Barnaby, Omar S.

AU - Hoy, K. S.

AU - Wa, Chunling

AU - DeBolt, Erin

AU - Koke, Michelle

AU - Hage, David S.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Glycation involves the non-enzymatic addition of reducing sugars and/or their reactive degradation products to amine groups on proteins. This process is promoted by the presence of elevated blood glucose concentrations in diabetes and occurs with various proteins that include human serum albumin (HSA). This review examines work that has been conducted in the study and analysis of glycated HSA. The general structure and properties of HSA are discussed, along with the reactions that can lead to modification of this protein during glycation. The use of glycated HSA as a short-to-intermediate term marker for glycemic control in diabetes is examined, and approaches that have been utilized for measuring glycated HSA are summarized. Structural studies of glycated HSA are reviewed, as acquired for both in vivo and in vitro glycated HSA, along with data that have been obtained on the rate and thermodynamics of HSA glycation. In addition, this review considers various studies that have investigated the effects of glycation on the binding of HSA with drugs, fatty acids and other solutes and the potential clinical significance of these effects.

AB - Glycation involves the non-enzymatic addition of reducing sugars and/or their reactive degradation products to amine groups on proteins. This process is promoted by the presence of elevated blood glucose concentrations in diabetes and occurs with various proteins that include human serum albumin (HSA). This review examines work that has been conducted in the study and analysis of glycated HSA. The general structure and properties of HSA are discussed, along with the reactions that can lead to modification of this protein during glycation. The use of glycated HSA as a short-to-intermediate term marker for glycemic control in diabetes is examined, and approaches that have been utilized for measuring glycated HSA are summarized. Structural studies of glycated HSA are reviewed, as acquired for both in vivo and in vitro glycated HSA, along with data that have been obtained on the rate and thermodynamics of HSA glycation. In addition, this review considers various studies that have investigated the effects of glycation on the binding of HSA with drugs, fatty acids and other solutes and the potential clinical significance of these effects.

KW - Diabetes

KW - Drug-protein binding

KW - Glycated albumin

KW - Glycation

KW - Human serum albumin

KW - Protein modification

UR - http://www.scopus.com/inward/record.url?scp=84883634135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883634135&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2013.07.013

DO - 10.1016/j.cca.2013.07.013

M3 - Review article

C2 - 23891854

AN - SCOPUS:84883634135

VL - 425

SP - 64

EP - 76

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -